ArticleNeuroradiology2026
One-and-done middle meningeal artery embolization with next-generation optiblock coils: streamlining workflow for chronic subdural hematoma.
Article in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMiddle meningeal artery (MMA) embolization is an adjunct or alternative to surgery for chronic subdural hematoma (cSDH), but data on coil-forward strategies remain limited. The purpose of this study is to evaluate safety and outcomes after MMA embolization using Optiblock coils engineered for efficient mechanical vessel occlusion.
methodsClinical data was extracted for a retrospective cohort of adults treated from February 2023 to December 2024 with ≥ 1 Optiblock coil; adjunctive embolic agent allowed. Symptoms, modified Rankin Scale (mRS), maximal SDH thickness, and midline shift were assessed at serial timepoints. McNemar's test and the Friedman test were used for longitudinal comparisons, with α = 0.05.
resultsThirty-one patients underwent embolization (mean age 74.0; 84% male). Procedures used a mean of 1.28 coils with an average total coil length of 27.2 cm. The most common Optiblock coil used was 3.5 mm x 20 cm. Embospheres (MERIT medical) were used as an adjunct in 87% of cases. Mean SDH thickness decreased from 14.8 mm pre-operatively to 8.9, 4.4, and 2.1 mm at ~ 1, 3, and 6 months post-operation (p < 0.05), corresponding to 40%, 71%, and 86% reductions; midline shift decreased concordantly (p < 0.05). mRS improved from 2.2 at baseline to 0.6 and 0.1 at first and last follow-up, respectively (p < 0.001). No periprocedural complications were noted. Interval surgical drainage was performed in 2 patients (6.5%) after initial isolated MMA embolization. Two delayed deaths occurred, both from known cardiovascular conditions unrelated to embolization.
conclusionOptiblock-based MMA embolization was associated with low complication and reintervention rates and substantial clinical, functional, and radiographic improvement. These coils offer an efficient alternative and/or adjunct to liquid/particle embolization, particularly in cases where particle or liquid embolization is contraindicated or technically unfeasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.